STOCK TITAN

[SCHEDULE 13G/A] AngioDynamics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Armistice Capital and Steven Boyd report a passive 3.76% stake in AngioDynamics (ANGO). The filing states Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., and Steven Boyd, as managing member, share voting and dispositive power over 1,527,815 shares. The stake is based on 40,633,885 shares outstanding as of May 31, 2025, per the issuer's 10-K. The Reporting Persons state the holdings were acquired in the ordinary course of business and not to influence control of the company. The Master Fund is the direct holder while Armistice exercises voting and investment authority under an investment management agreement.

Armistice Capital e Steven Boyd dichiarano una partecipazione passiva del 3,76% in AngioDynamics (ANGO). La comunicazione indica che Armistice Capital, in qualità di gestore degli investimenti per Armistice Capital Master Fund Ltd., e Steven Boyd, in qualità di membro amministratore, detengono congiuntamente il diritto di voto e il potere dispositivivo su 1.527.815 azioni. La quota si basa su 40.633.885 azioni in circolazione al 31 maggio 2025, secondo il 10-K dell'emittente. I soggetti segnalanti dichiarano che le partecipazioni sono state acquisite nell'ordinaria attività di business e non con l'intento di influenzare il controllo della società. Il Master Fund è il detentore diretto, mentre Armistice esercita l'autorità di voto e di investimento in base a un accordo di gestione degli investimenti.

Armistice Capital y Steven Boyd informan una participación pasiva del 3,76% en AngioDynamics (ANGO). El reporte señala que Armistice Capital, como gestor de inversiones de Armistice Capital Master Fund Ltd., y Steven Boyd, como miembro gerente, comparten el poder de voto y dispositive sobre 1.527.815 acciones. La participación se calcula sobre 40.633.885 acciones en circulación al 31 de mayo de 2025, según el 10-K del emisor. Las personas informantes afirman que las tenencias se adquirieron en el curso ordinario del negocio y no para influir en el control de la compañía. El Master Fund es el titular directo, mientras que Armistice ejerce la autoridad de voto e inversión bajo un acuerdo de gestión de inversiones.

암미스티스 캐피털(Armistice Capital)과 스티븐 보이드(Steven Boyd)가 앤지오다이내믹스(AngioDynamics, ANGO)의 3.76% 수동적 지분을 신고했습니다. 제출서류에 따르면 암미스티스 캐피털은 Armistice Capital Master Fund Ltd.의 투자 매니저로서, 스티븐 보이드는 매니징 멤버로서 각각 또는 공동으로 1,527,815주에 대한 의결권 및 처분권을 보유하고 있습니다. 이 지분은 발행사가 제출한 2025년 5월 31일 기준 40,633,885주의 유통 주식을 기준으로 산정되었습니다(10-K 기준). 보고인은 보유 주식이 통상적인 영업활동 중에 취득된 것이며 회사의 지배권을 행사하려는 목적이 아니라고 명시했습니다. 마스터 펀드가 직접 보유자이며, 암미스티스는 투자운용계약에 따라 의결권 및 투자권한을 행사합니다.

Armistice Capital et Steven Boyd déclarent une participation passive de 3,76 % dans AngioDynamics (ANGO). Le dépôt indique qu’Armistice Capital, en tant que gestionnaire d’investissement de Armistice Capital Master Fund Ltd., et Steven Boyd, en qualité de membre dirigeant, partagent le pouvoir de vote et le pouvoir de disposition sur 1 527 815 actions. La participation est calculée sur la base de 40 633 885 actions en circulation au 31 mai 2025, selon le 10‑K de l’émetteur. Les personnes déclarante précisent que les avoirs ont été acquis dans le cours normal des affaires et non dans le but d’influencer le contrôle de la société. Le Master Fund est le détenteur direct, tandis qu’Armistice exerce l’autorité de vote et d’investissement en vertu d’un contrat de gestion d’investissements.

Armistice Capital und Steven Boyd melden eine passive Beteiligung von 3,76% an AngioDynamics (ANGO). Die Meldung besagt, dass Armistice Capital als Investmentmanager für Armistice Capital Master Fund Ltd. und Steven Boyd als geschäftsführendes Mitglied gemeinschaftlich Stimm- und Verfügungsgewalt über 1.527.815 Aktien ausüben. Die Beteiligung basiert auf 40.633.885 ausstehenden Aktien zum 31. Mai 2025, laut dem 10-K des Emittenten. Die meldepflichtigen Personen geben an, die Bestände im gewöhnlichen Geschäftsverlauf erworben zu haben und nicht mit der Absicht, die Kontrolle über das Unternehmen zu beeinflussen. Der Master Fund ist der direkte Inhaber, während Armistice die Stimm- und Investmentbefugnis im Rahmen eines Investment-Management-Vertrags ausübt.

Positive
  • Transparent disclosure of beneficial ownership and the relationship between Armistice Capital, the Master Fund, and Steven Boyd
  • Position is passive and under 5%, indicating no immediate intent to influence control
Negative
  • None.

Insights

TL;DR: Institutional manager reports a non-controlling 3.76% position, disclosed for regulatory transparency.

The Schedule 13G/A shows Armistice Capital, via its Master Fund, holds 1,527,815 AngioDynamics shares representing 3.76% of the reported float. This level is below the 5% threshold that typically triggers Schedule 13D obligations, indicating a passive investor posture. The filing clarifies voting and dispositive powers are exercised by Armistice under an investment management agreement and that holdings are ordinary-course investments, which reduces the likelihood of imminent activism or control attempts.

TL;DR: Disclosure aligns with governance norms; no material control implications.

The joint filing and certifications are standard: Armistice and Steven Boyd file jointly and disclaim control beyond managerial authority. The explicit statement that the Master Fund disclaims beneficial ownership due to its agreement with Armistice is important for legal clarity. Because the position is under 5% and accompanied by a passive declaration, this is a routine ownership disclosure with limited immediate governance impact.

Armistice Capital e Steven Boyd dichiarano una partecipazione passiva del 3,76% in AngioDynamics (ANGO). La comunicazione indica che Armistice Capital, in qualità di gestore degli investimenti per Armistice Capital Master Fund Ltd., e Steven Boyd, in qualità di membro amministratore, detengono congiuntamente il diritto di voto e il potere dispositivivo su 1.527.815 azioni. La quota si basa su 40.633.885 azioni in circolazione al 31 maggio 2025, secondo il 10-K dell'emittente. I soggetti segnalanti dichiarano che le partecipazioni sono state acquisite nell'ordinaria attività di business e non con l'intento di influenzare il controllo della società. Il Master Fund è il detentore diretto, mentre Armistice esercita l'autorità di voto e di investimento in base a un accordo di gestione degli investimenti.

Armistice Capital y Steven Boyd informan una participación pasiva del 3,76% en AngioDynamics (ANGO). El reporte señala que Armistice Capital, como gestor de inversiones de Armistice Capital Master Fund Ltd., y Steven Boyd, como miembro gerente, comparten el poder de voto y dispositive sobre 1.527.815 acciones. La participación se calcula sobre 40.633.885 acciones en circulación al 31 de mayo de 2025, según el 10-K del emisor. Las personas informantes afirman que las tenencias se adquirieron en el curso ordinario del negocio y no para influir en el control de la compañía. El Master Fund es el titular directo, mientras que Armistice ejerce la autoridad de voto e inversión bajo un acuerdo de gestión de inversiones.

암미스티스 캐피털(Armistice Capital)과 스티븐 보이드(Steven Boyd)가 앤지오다이내믹스(AngioDynamics, ANGO)의 3.76% 수동적 지분을 신고했습니다. 제출서류에 따르면 암미스티스 캐피털은 Armistice Capital Master Fund Ltd.의 투자 매니저로서, 스티븐 보이드는 매니징 멤버로서 각각 또는 공동으로 1,527,815주에 대한 의결권 및 처분권을 보유하고 있습니다. 이 지분은 발행사가 제출한 2025년 5월 31일 기준 40,633,885주의 유통 주식을 기준으로 산정되었습니다(10-K 기준). 보고인은 보유 주식이 통상적인 영업활동 중에 취득된 것이며 회사의 지배권을 행사하려는 목적이 아니라고 명시했습니다. 마스터 펀드가 직접 보유자이며, 암미스티스는 투자운용계약에 따라 의결권 및 투자권한을 행사합니다.

Armistice Capital et Steven Boyd déclarent une participation passive de 3,76 % dans AngioDynamics (ANGO). Le dépôt indique qu’Armistice Capital, en tant que gestionnaire d’investissement de Armistice Capital Master Fund Ltd., et Steven Boyd, en qualité de membre dirigeant, partagent le pouvoir de vote et le pouvoir de disposition sur 1 527 815 actions. La participation est calculée sur la base de 40 633 885 actions en circulation au 31 mai 2025, selon le 10‑K de l’émetteur. Les personnes déclarante précisent que les avoirs ont été acquis dans le cours normal des affaires et non dans le but d’influencer le contrôle de la société. Le Master Fund est le détenteur direct, tandis qu’Armistice exerce l’autorité de vote et d’investissement en vertu d’un contrat de gestion d’investissements.

Armistice Capital und Steven Boyd melden eine passive Beteiligung von 3,76% an AngioDynamics (ANGO). Die Meldung besagt, dass Armistice Capital als Investmentmanager für Armistice Capital Master Fund Ltd. und Steven Boyd als geschäftsführendes Mitglied gemeinschaftlich Stimm- und Verfügungsgewalt über 1.527.815 Aktien ausüben. Die Beteiligung basiert auf 40.633.885 ausstehenden Aktien zum 31. Mai 2025, laut dem 10-K des Emittenten. Die meldepflichtigen Personen geben an, die Bestände im gewöhnlichen Geschäftsverlauf erworben zu haben und nicht mit der Absicht, die Kontrolle über das Unternehmen zu beeinflussen. Der Master Fund ist der direkte Inhaber, während Armistice die Stimm- und Investmentbefugnis im Rahmen eines Investment-Management-Vertrags ausübt.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:08/14/2025
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:08/14/2025
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

How many AngioDynamics (ANGO) shares does Armistice Capital report owning?

The filing reports 1,527,815 shares beneficially owned by the Reporting Persons.

What percentage of ANGO does the reported position represent?

The position represents 3.76% of the class, based on 40,633,885 shares outstanding as of May 31, 2025.

Does Armistice Capital claim control of AngioDynamics?

No. The filing states the holdings were acquired and are held in the ordinary course of business and not to change or influence control.

Who holds the shares directly and who manages voting rights?

The Armistice Capital Master Fund Ltd. is the direct holder; Armistice Capital, as investment manager, exercises voting and investment power under an investment management agreement.

When was the Schedule 13G/A signed?

The signatures are dated August 14, 2025.
Angiodynamics

NASDAQ:ANGO

ANGO Rankings

ANGO Latest News

ANGO Latest SEC Filings

ANGO Stock Data

368.14M
37.50M
6.84%
93.27%
7.38%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
LATHAM